New drug combo fails to advance in resistant breast cancer trial
Disease control
Terminated
This study tested a combination of two oral drugs, BKM120 and lapatinib, in people with a specific type of advanced breast cancer (HER2-positive) that had stopped responding to the standard drug trastuzumab. The goal was to see if the combination was safe and could shrink tumors.…
Phase: PHASE1, PHASE2 • Sponsor: Institut Paoli-Calmettes • Aim: Disease control
Last updated Apr 29, 2026 02:06 UTC